DOCSLIB.ORG

Vaccinate Adults October 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Volume 18 – Number 3 October 2014 (Content current VACCINATE ADULTS! as of October 21) from the Immunization Action Coalition — www.immunize.org New ACIP Recommendations Include Important Changes What’s In This Issue for the Use of Influenza and Pneumococcal Vaccines ACIP Recommendations: An Update ...... ......... 1 Ask The Experts: CDC Answers Questions ....... 1 Influenza Vaccination New! Visit “Adult Vaccination” on Immunize.org... 2 The Centers for Disease Control and Prevention tions of ACIP” in MMWR available at www.cdc. Vaccine Highlights ............................................ 4 (CDC) published its updated influenza recommen- gov/mmwr/pdf/wk/mm6337.pdf, pages 822–825. dations titled “Prevention and Control of Seasonal It is now recommended that all adults age 65 Checklist for Vaccine Contraindications ............ 5 Influenza with Vaccines: Recommendations of years and older receive both pneumococcal con- New! Standing Orders: How to Use Them…. .... 6 ACIP—U.S., 2014–15 Influenza Season” in the jugate vaccine (PCV13, Prevnar 13, Pfizer) and Medical Management of Vaccine Reactions ...... 7 August 15 issue of MMWR available at www.cdc. pneumococcal polysaccharide vaccine (PPSV23, New! Foodborne Hepatitis A Outbreaks . .......... 8 gov/mmwr/pdf/wk/mm6332.pdf, pages 691–697. Pneumovax, Merck). Both PCV13 and PPSV23 New! Patient Handouts on Hepatitis A Vaccine ... 9 All people age 6 months and older who do not have should be administered routinely in series to all CDC Fact Sheet: Adult Pneumococcal Vaccines ... 10 contraindications should receive influenza vacci- adults age 65 years and older. For specific details about timing and spacing of these doses, refer to 2014–15 Influenza VISs in Many Languages ... 11 nation annually—this has been a core ACIP recom- mendation since the 2010–11 influenza season. For the published recommendations as well as IAC’s Mandatory Influenza Vaccination Policies .....12-13 IAC’s up-to-date screening checklists for precau- “Ask the Experts” on page 23. Also, see page 10 for Screening Checklists for Contraindications tions and contraindications to influenza vaccina- a two-page CDC fact sheet for patients and provid- to Influenza Vaccines.....................................14-15 tion for adults, see pages 14 and 15 of this issue. ers titled “Pneumococcal Vaccines (PCV13) and Standing Orders for Influenza Vaccines......... ... 16 For complete details about influenza vaccine (PPSV23): Addressing Common Questions about Influenza Vaccination and Egg Allergy .............. 17 use in 2014–15, including contraindications and Pneumococcal Vaccination for Adults.” Influenza Materials for Healthcare Professionals ... 18 precautions, consult the ACIP recommendations. Influenza Handouts for Patients ........................ 19 Influenza Vaccine Products for 2014–2015 ....... 20 Pneumococcal Vaccination Immunization questions? On September 19, CDC published “Use of How to Give IM, ID, and IN Flu Vaccines .......... 21 13-Valent Pneumococcal Conjugate Vaccine and • Email [email protected] Seek Emergency Medical Care for Your Family ... 22 23-Valent Pneumococcal Polysaccharide Vaccine • Call your state health dept. (phone numbers IAC’s Immunization Resources Order Form ...... 24 Among Adults Aged ≥65 Years: Recommenda- at www.immunize.org/coordinators) severe allergy to eggs with symptoms sugges- older. Can we give both vaccines at the same Ask the tive of anaphylaxis, then the provider can use a visit? recombinant influenza vaccine (RIV3, Flublok, According to the ACIP recommendations pub- Protein Sciences) that is egg-free. Unlike current lished in September 2014, both pneumococcal Experts production methods for other available seasonal conjugate vaccine (PCV13, Prevnar 13, Pfizer) and influenza vaccines, production of RIV3 does not pneumococcal polysaccharide vaccine (PPSV23, use the whole influenza virus or chicken eggs in Pneumovax, Merck) should be administered its manufacturing process. If RIV3 is not available routinely in a series to all adults age 65 years and or the person is not age-eligible, then inactivated ▲ Ask the Experts . continued on page 23 influenza vaccine should be administered by a physician with experience in the recognition and management of severe allergic conditions. FEDERAL and A study has now been published (N Engl J MILITARY Med 2014; 371:635–45) that found that the injectable vaccine Fluzone High-Dose (Sanofi) EMPLOYEES protects people 65 years and older better than Donna L. Weaver, RN, MN Andrew T. Kroger, MD, MPH standard-dose Fluzone. Does ACIP preferen- Make the tially recommend use of Fluzone High-Dose The Immunization Action Coalition thanks medi- for all people age 65 years and older? Immunization Action Coalition cal officer Andrew T. Kroger, MD, MPH, and Despite published evidence of better protection your charity of choice for the nurse educator Donna L. Weaver, RN, MN, both from Fluzone High-Dose when compared to Combined Federal Campaign. from the National Center for Immunization and standard-dose Fluzone, ACIP has not stated a Respiratory Diseases at the Centers for Disease Use agency code Control and Prevention. preference for this vaccine for people age 65 years and older. #10612 Influenza vaccine The Immunization Action Coalition Pneumococcal vaccine is a 501(c)(3) charitable organization I’ve heard there is a newer influenza vaccine and your contribution is tax-deductible Please describe the new ACIP recommenda- that can be given to people with severe egg to the fullest extent of the law. allergy. Is that true? tions for the use of PCV13 vaccine along with Yes. If someone age 18 through 49 years has a PPSV23 vaccine in people age 65 years and Vaccinate Adults! online at www.immunize.org/va Immunization Action Coalition New! Visit “Adult Vaccination” 2550 University Ave. W., Suite 415 North Saint Paul, MN 55114 Phone: (651) 647-9009 on immunize.org Email: [email protected] To provide one-stop access to practical and clinically Websites: www.immunize.org www.vaccineinformation.org relevant information about vaccinating adults, www.immunizationcoalitions.org the Immunization Action Coalition (IAC) has Vaccinate Adults is a publication of the developed a new section on immunize.org titled Immunization Action Coalition (IAC) writ- “Adult Vaccination.” Visit www.immunize.org/adult- ten for health professionals. Content is re- vaccination often! viewed by the Centers for Disease Control and Prevention (CDC) for technical accuracy. The new web page brings together resources from This publication is supported by CDC Grant No. U38IP000589. The content is solely the multiple sources, including CDC, the National Vaccine responsibility of IAC and does not neces- Advisory Committee (NVAC), state health depart- sarily represent the official views of CDC. ments, professional societies, medical journals, and ISSN 1526-1824. IAC. You’ll find helpful vaccination-related resources, Publication Staff Executive Editor: Deborah L. Wexler, MD such as Advisory Committee on Immunization Prac- Editor: Mary Quirk tices (ACIP) recommendations, educational materials Associate Editor: Diane C. Peterson for healthcare providers, videos, selected journal Consulting Editors: Teresa Anderson, DDS, articles, patient handouts, PowerPoint presentations, MPH; Marian Deegan, JD; Linda Moyer, RN and much more. Editorial Assistant: Janelle T. Anderson, MA Layout: Kathy Cohen Adult Vaccination Resources Library Website Design: Sarah Joy IAC’s online library gives healthcare providers and www.immunize.org/adult-vaccination IAC Staff the general public quick access to reliable, science- Chief Strategy Officer: L.J (Litjen) Tan, MS, PhD based information about adult immunization. Recently updated, the IAC library now includes approximately Assoc. Director for Immunization Education: that their adult patients are fully immunized and have William L. Atkinson, MD, MPH 250 adult immunization resources from a variety of maximum protection from serious diseases. CDC has Associate Director for Research: sources. Materials are available in many media formats, created new materials to assist healthcare professionals Sharon G. Humiston, MD, MPH including print, video, online, web-on-demand, and in implementing NVAC's new standards, including a Coordinator for Public Health: interactive. Access the library at www.immunize.org/ Laurel Wood, MPA series of fact sheets encouraging improvement of vac- adult-vaccination/resources.asp. Coordinator for Hepatitis B Projects: cine assessment, recommendation, administration, and Lynn Pollock, RN, MSN referral. Access information on the NVAC standards at Adult Handouts for Patients and Staff Sr. Admin. for Grants and Leadership: www.immunize.org/adult-vaccination. Julie Murphy, MA IAC’s new Adult Vaccination Handouts section, www. Operations Manager: Robin VanOss immunize.org/handouts/adult-vaccination.asp, features Journal Articles Associate Operations Manager: Casey Pauly more than 50 educational pieces for healthcare profes- Be sure to check out IAC’s newest resource listing of IAC publishes a free email news service (IAC sionals and their patients. From screening checklists more than 100 key medical journal articles about adult Express) and two free periodicals (Needle to patient information materials, this collection helps Tips and Vaccinate Adults). To subscribe, go vaccination at www.immunize.org/journalarticles/ you carry out your vaccination activities. Several pa- to www.immunize.org/subscribe. peop_adults.asp. IAC, a 501(c)(3) charitable organization,
Recommended publications
  • 362.Full.Pdf

    362.Full.Pdf

    AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis ABSTRACT. Heptavalent pneumococcal conjugate vac- lular pertussis; HbOC, Haemophilus influenzae type b conjugate cine (PCV7) is recommended for universal use in chil- vaccine; HIV, human immunodeficiency virus; AOM, acute otitis dren 23 months and younger, to be given concurrently media. with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months he purpose of this report is to provide recom- old who have not received previous doses of PCV7, ad- ministration of a reduced number of doses is recom- mendations for use of the heptavalent pneumo- mended. Two doses of PCV7 are recommended for chil- Tcoccal conjugate vaccine (PCV7), Prevnar (Led- dren 24 to 59 months old at high risk of invasive erle Laboratories, Pearl River, NY; Wyeth-Ayerst pneumococcal infection—including children with func- Pharmaceuticals, Marietta, PA), and 23-valent pneumo- tional, anatomic, or congenital asplenia; infection with coccal polysaccharide (23PS) vaccines. In addition, rec- human immunodeficiency virus; and other predisposing ommendations for the continuing use of antibiotic pro- conditions—who have not been immunized previously phylaxis in children with sickle cell disease (SCD) and with PCV7. Recommendations have been made for use of asplenia will be given, and the use of antibiotics and 23-valent pneumococcal polysaccharide (23PS) vaccine in vaccines in children who attend out-of-home care will high-risk children to expand serotype coverage.
  • Gamma-Irradiated SARS-Cov-2 Vaccine Candidate, OZG-38.61.3, Confers Protection from SARS-Cov-2 Challenge in Human ACEII-Transgen

    Gamma-Irradiated SARS-Cov-2 Vaccine Candidate, OZG-38.61.3, Confers Protection from SARS-Cov-2 Challenge in Human ACEII-Transgen

    www.nature.com/scientificreports OPEN Gamma‑irradiated SARS‑CoV‑2 vaccine candidate, OZG‑38.61.3, confers protection from SARS‑CoV‑2 challenge in human ACEII‑transgenic mice Raife Dilek Turan1,2,19, Cihan Tastan1,3,4,19*, Derya Dilek Kancagi1,19, Bulut Yurtsever1,19, Gozde Sir Karakus1,19, Samed Ozer5, Selen Abanuz1,6, Didem Cakirsoy1,8, Gamze Tumentemur7, Sevda Demir2, Utku Seyis1, Recai Kuzay1, Muhammer Elek1,2, Miyase Ezgi Kocaoglu1, Gurcan Ertop7, Serap Arbak9, Merve Acikel Elmas9, Cansu Hemsinlioglu1, Ozden Hatirnaz Ng10, Sezer Akyoney10,11, Ilayda Sahin8,12, Cavit Kerem Kayhan13, Fatma Tokat14, Gurler Akpinar15, Murat Kasap15, Ayse Sesin Kocagoz16, Ugur Ozbek12, Dilek Telci2, Fikrettin Sahin2, Koray Yalcin1,17, Siret Ratip18, Umit Ince14 & Ercument Ovali1 The SARS‑CoV‑2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma‑irradiated inactivated virus vaccine does not require an extra purifcation process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG‑38.61.3) is that it is a non‑adjuvant added, gamma‑irradiated, and intradermally applied inactive viral vaccine. Efciency and safety dose (either 1013 or 1014 viral RNA copy per dose) of OZG‑38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efcacy of the vaccine. Human ACE2‑encoding transgenic mice were immunized and then infected with the SARS‑CoV‑2 virus for the challenge test.
  • (ACIP) General Best Guidance for Immunization

    (ACIP) General Best Guidance for Immunization

    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
  • COVID-19 Vaccination Strategy in China: a Case Study

    COVID-19 Vaccination Strategy in China: a Case Study

    Article COVID-19 Vaccination Strategy in China: A Case Study Marjan Mohamadi 1,†, Yuling Lin 1,*,† ,Mélissa Vuillet Soit Vulliet 1,†, Antoine Flahault 1, Liudmila Rozanova 1 and Guilhem Fabre 2 1 Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland; [email protected] (M.M.); [email protected] (M.V.S.V.); antoine.fl[email protected] (A.F.); [email protected] (L.R.) 2 Department of Chinese, UFR 2, Université Paul Valéry Montpellier 3, 34199 Montpellier, France; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with Citation: Mohamadi, M.; Lin, Y.; 483.34 million doses having been administered across the country by 21 May 2021. China is also Vulliet, M.V.S.; Flahault, A.; acting as an important player in the development and production of SARS-CoV-2 vaccines.
  • Pneumococcal Vaccine Timing for Adults Make Sure Your Patients Are up to Date with Pneumococcal Vaccination

    Pneumococcal Vaccine Timing for Adults Make Sure Your Patients Are up to Date with Pneumococcal Vaccination

    Pneumococcal Vaccine Timing for Adults Make sure your patients are up to date with pneumococcal vaccination. When both are If either vaccine is PCV13 and PPSV23 Two pneumococcal vaccines are recommended for adults: indicated, PCV13 inadvertently given should not be 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®) should be given earlier than the administered during the ® before PPSV23 recommended window, 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23) same office visit. whenever possible. do not repeat the dose. One dose of PCV13 is recommended for adults: One dose of PPSV23 is recommended for adults: 19 years or older with certain medical conditions and who have not 65 years or older, regardless of previous history of vaccination with previously received PCV13. See Table 1 for specific guidance. pneumococcal vaccines. Adults 65 years or older can discuss and decide, with their clinician, – Once a dose of PPSV23 is given at age 65 years or older, no to receive PCV13 if they have not previously received a dose (shared additional doses of PPSV23 should be administered. clinical decision-making). 19 through 64 years with certain medical conditions. – A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance. Adults 65 years or older without an immunocompromising condition, CSF* leak, or cochlear implant For those who have not received any pneumococcal For those who have previously received 1 dose of vaccines, or those with unknown vaccination history PPSV23 at ≥ 65 years and no doses of PCV13 If patient and provider decide PCV13 is not to be given: If patient and provider decide PCV13 is not to be given: Administer 1 dose of PPSV23.
  • Immunisation How Vaccines Work

    Immunisation How Vaccines Work

    Immunisation How vaccines work Dr Fiona Ryan Consultant in Public Health Medicine, Department of Public Health April 2015 Presentation Outline • An understanding of the following principles • Overview of immunity • Different types of vaccines and vaccine contents • Vaccine failures • Time intervals between vaccine doses • Vaccine overload • Adverse reactions • Herd immunity Immunity Immunity • – The ability of the human body to protect itself from infectious disease The immune system • Cells with a protective function in the – bone marrow –thymus – lymphatic system of ducts and nodes – spleen – blood Types of immunity Source: http://en.wikipedia.org/wiki/Immunological_memory Natural (innate) immunity Non-specific mechanisms – Physical barriers • skin and mucous membranes – Chemical barriers • gastric and digestive enzymes – Cellular and protein secretions • phagocytes, macrophages, complement system ** No “memory” of protection exists afterwards ** Passive immunity – adaptive mechanisms Natural • maternal transfer of antibodies to infant via placenta Artificial • administration of pre- formed substance to provide immediate but short-term protection (anti- toxin, antibodies) Protection is temporary and wanes with time (usually few months) Active immunity – adaptive mechanisms Natural • following contact with organism Artificial • administration of agent to stimulate immune response (immunisation) Acquired through contact with an micro-organism Protection produced by individual’s own immune system Protection often life-long but may need
  • Adults with DIABETES Are Among Those Who Need Pneumococcal

    Adults with DIABETES Are Among Those Who Need Pneumococcal

    Patients with diabetes are at an increased risk for complications from pneumococcal disease. Diabetes may be a unique risk factor for increased incidence of sepsis associated with pneumococcal infection. One of the reasons people with diabetes are at greater risk for pneumococcal disease is that they may have abnormalities in immune function that affect their reaction to infection. Pneumococcal disease causes serious illnesses like pneumonia, meningitis, and sepsis. Pneumococcal disease is serious and deadly. In the US, pneumococcal pneumonia, meningitis, and sepsis kill tens of thousands each year. Pneumococcal disease survivors may suffer hearing loss, seizures, blindness, or paralysis. Pneumococcal vaccination is recommended for all adults with diabetes. Adults with DIABETES Are Among Those Who Need Pneumococcal Vaccination There are two types of pneumococcal vaccine recommended for US adults: a pneumococcal conjugate vaccine (PCV13) and a pneumococcal polysaccharide vaccine (PPSV23). Adults 65 and older, and adults age 19 to 64 years with any of the following need to receive both vaccines: immunocompromising conditions or treatments (e.g., HIV/AIDS, leukemia, lymphoma, Hodgkin disease, radiation therapy); a damaged or missing spleen; cochlear implants; or cerebrospinal fluid leaks. Other adults for whom pneumococcal vaccination is recommended only need PPSV23, but may need more than one dose and will need PCV13 when they, too, reach age 65. Please refer to the Adult Pneumococcal Vaccination Guide or visit cdc.gov/vaccines/vpd-vac/pneumo/ for details on timing of vaccine doses. For more information and resources to educate patients about pneumococcal disease, visit adultvaccination.org/professional-resources/pneumo This initiative is supported by unrestricted educational grants from Merck & Co., Inc.
  • Immunity and How Vaccines Work

    Immunity and How Vaccines Work

    Immunity and how vaccines work Dr Brenda Corcoran National Immunisation Office Presentation Outline An understanding of the following principles: • Overview of immunity • Different types of vaccines and vaccine contents • Vaccine failures • Time intervals between vaccine doses • Vaccine overload • Adverse reactions • Herd immunity Immunity Immunity • The ability of the human body to protect itself from infectious disease The immune system • Cells with a protective function in the – bone marrow – thymus – lymphatic system of ducts and nodes – spleen –blood Types of immunity Source: http://en.wikipedia.org/wiki/Immunological_memory Natural (innate) immunity Non-specific mechanisms – Physical barriers • skin and mucous membranes – Chemical barriers • gastric and digestive enzymes – Cellular and protein secretions • phagocytes, macrophages, complement system ** No “memory” of protection exists afterwards ** Passive immunity – adaptive mechanisms Natural • maternal transfer of antibodies to infant via placenta Artificial • administration of pre- formed substance to provide immediate but short-term protection (antitoxin, antibodies) Protection is temporary and wanes with time (usually few months) Active immunity – adaptive mechanisms Natural • following contact with organism Artificial • administration of agent to stimulate immune response (immunisation) Acquired through contact with an micro-organism Protection produced by individual’s own immune system Protection often life-long but may need boosting How vaccines work • Induce active immunity – Immunity and immunologic memory similar to natural infection but without risk of disease • Immunological memory allows – Rapid recognition and response to pathogen – Prevent or modify effect of disease Live attenuated vaccines Weakened viruses /bacteria – Achieved by growing numerous generations in laboratory – Produces long lasting immune response after one or two doses – Stimulates immune system to react as it does to natural infection – Can cause mild form of the disease (e.g.
  • COVID-19 Vaccine-Mediated Enhanced Disease (VMED)

    COVID-19 Vaccine-Mediated Enhanced Disease (VMED)

    COVID-19 Vaccine-Mediated Enhanced Disease and Vaccine Effectiveness in the Vaccine Safety Datalink VSD Study #1341 PROTOCOL VERSION: 1.2 DATE: 27 April 2021 KEY STUDY STAFF Marshfield Clinic Research Institute (MCRI) Principal Investigator Edward Belongia, MD Co-Investigators Thomas Boyce, MD, MPH James Donahue, DVM, PhD Dave McClure, PhD Biostatistician Burney Kieke Jr., MS Project Managers Kayla Hanson, MPH Hannah Berger, MPH Data Manager Erica Scotty, MS Project Administrator Bobbi Bradley, MPH, MBA Vaccine Safety Datalink Collaborating Site Investigators and Project Managers Denver Health Joshua Williams, MD Jonathan Block, MEd, PMP Harvard Pilgrim Katherine Yih, PhD, MD Jessica LeBlanc, MPH HealthPartners Malini DeSilva, MD, MPH Leslie Kuckler, MPH Kaiser Permanente Matt Daley, MD Colorado Jo Ann Shoup, PhD Kaiser Permanente Nicky Klein, MD, PhD Northern California Kristin Goddard, MPH (AIM 2) Kaiser Permanente Stephanie Irving, MHS Northwest Tia Kauffman, MPH Kaiser Permanente Bruno Lewin, MD Southern California Cheryl Carlson, MPH (AIM 2) Denison Ryan, MPH Kaiser Permanente Lisa Jackson, MD, MPH Washington Erika Kiniry, MPH Centers for Disease Control and Prevention (CDC) Investigators Immunization Safety Jonathan Duffy, MD, MPH Office Michael McNeil, MD, MPH COVID-19 VE Team TBN Page ii PROTOCOL CHANGE HISTORY Version/Date Summary of Change 1.0/26 March 2021 Original protocol 1.1/21 April 2021 Minor revisions to eligibility criteria, exposure classification, and covariates 1.2/27 April 2021 Minor revisions to data lag and Aim 2 endpoints PROTOCOL SYNOPSIS Title: COVID-19 VMED and Vaccine Effectiveness in the VSD Short name: COVID-19 VMED/VE Study Rationale Vaccine-mediated enhanced disease (VMED) can result from immune complex formation and Th2 biased cellular immune response when vaccinated individuals become infected with the target pathogen.
  • 2021 Medicare Vaccine Coverage Part B Vs Part D

    2021 Medicare Vaccine Coverage Part B Vs Part D

    CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac­ • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert,
  • Global Immunization News 25 February 2011

    Global Immunization News 25 February 2011

    Global Immunization News 25 February 2011 World Health Organization Global Immunization News Inside this issue: Technical Information Meeting of the Global Advisory 2 Committee on Vaccine Safety Polio eradication mourns loss of 2 NEW VACCINES, NEW true polio champion OPPORTUNITIES Announcements from The SIVAC 3 25/02/2011 from Hayatee Hasan, WHO/HQ Initiative In the past two months, four countries ― WHO position on pandemic influ- 3 Guyana, Kenya, Sierra Leone and Yemen ― enza vaccination following reports of narcolepsy subsequent to use of have introduced the pneumococcal conjugate Pandemrix vaccine. They represent the first of a series of countries introducing the vaccine in 2011. PHOTO Cold Chain and Logistics Taskforce 3 WHO concludes that quality issues 4 These introductions represent a major relating to Quinvaxem production milestone - the gap between access to new have been resolved vaccines between developed and developing AFRICA 4-6 countries is shortening; it is extraordinary to The launching of the Pneumococcal see a new vaccine launched in a developing conjugate vaccine (PCV-13) in Si- erra Leone country within one to two years of its introduction in the Americas and Europe, Kenya launches ten-valent pneumo- while in the past, it has taken several years coccal conjugate vaccine (PCV10) Vaccine carrier containing pneumococcal vaccine in (averaging 15 years) between the Kenya Meetings held in afro central introduction of new vaccines in developed and developing countries. AMERICAS 6-8 Peru introduces nationwide HPV vaccination; Argentina announces For more information regarding the launches in these countries, please see the articles on HPV vaccine introduction Kenya, Sierra Leone and Yemen.
  • Reverse Genetic Platform for Inactivated and Live-Attenuated Influenza Vaccine

    Reverse Genetic Platform for Inactivated and Live-Attenuated Influenza Vaccine

    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 42, No. 2, 116-121, February 2010 Reverse genetic platform for inactivated and live-attenuated influenza vaccine Eun-Ju Jung, Kwang-Hee Lee vaccine for the prevention of influenza epidemics and and Baik Lin Seong1 pandemics. Department of Biotechnology Keywords: influenza vaccines; influenzavirus A; in- College of Bioscience and Biotechnology fluenzavirus B; orthomyxoviridae Translation Research Center for Protein Function Control Yonsei University Seoul 120-749, Korea Introduction 1Corresponding author: Tel, 82-2-2123-2885; Fax, 82-2-362-7265; E-mail, [email protected] Influenza viruses are members of orthomyxoviri- dae family and composed of 8 segmented nega- DOI 10.3858/emm.2010.42.2.013 tive-sense, single-stranded RNAs. Type A and B influenza viruses are the most important as human Accepted 30 November 2009 Available Online 7 January 2010 pathogens responsible for annual outbreaks of acute respiratory disease. A total of 16 haemagglu- Abbreviations: att, attenuation; ca, cold-adapted; rg, reverse genetic; tinin subtype and 9 neuraminidase subtype were ts, temperature-sensitive identified in influenza A type (Webby and Webster, 2001; Nicholson et al., 2003). Due to segmented nature of RNA genes, the virus can exchange their Abstract RNA segments genes with other subtypes of influenza viruses causing major changes of Influenza vaccine strains have been traditionally devel- antigenicity. In addition, the replication of the RNA oped by annual reassortment between vaccine donor genes is error-prone, allowing frequent nucleotide strain and the epidemic virulent strains. The classical substitutions at genetic level (Webby and Webster, method requires screening and genotyping of the vac- 2001).